Not finding it? Sign in to also search OpenAlex live.
-
P45 Combining clinical, biological, and health-related quality of life remission with endoscopic improvements: data from SELECTION2022 Poster presentations conference-abstract Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease
Ben Morison, Stefan Schreiber, Brian G. Feagan, Laurent Peyrin‐Biroulet, Severine A.R.A. Vermeire, Margaux Faes, +4 more
0citations -
P47 Re-treatment with filgotinib in patients with ulcerative colitis following treatment interruption: SELECTION and SELECTIONLTE data2022 Poster presentations conference-abstract Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease
Ben Morison, Severine Vermiere, Brian G. Feagan, Laurent Peyrin‐Biroulet, Alessandra Faria Oortwijn, Margaux Faes, +2 more
0citations -
P772 Comprehensive disease control in patients with Ulcerative Colitis: refinement of a multi-component endpoint using data from the filgotinib SELECTION trial2024 Journal of Crohn s and Colitis conference-abstract Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access
Stefan Schreiber, Brian G. Feagan, Severine A.R.A. Vermeire, Silvio Danese, Veerle Vyncke, Margaux Faes, +2 more
0citations -
POS0798 EFFICACY, SAFETY AND RADIOGRAPHIC OUTCOMES FROM THE PHASE 3 SELECT-AXIS 2 STUDY OF UPADACITINIB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS AND AN INADEQUATE RESPONSE TO BIOLOGIC DMARD THERAPY: 2-YEAR DATA2024 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments
X. Baraliakos, D. van der Heijde, J. Sieper, Robert Davies Inman, H. Kameda, Walter P. Maksymowych, +5 more
1citations -
POS0050 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 2-YEAR DATA FROM THE PHASE 3 SELECT-AXIS 2 STUDY2024 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments
Filip E Van den Bosch, Atul A. Deodhar, Denis Poddubnyy, Walter P. Maksymowych, Désirée M F M van der Heijde, T.-H. Kim, +7 more
0citations -
OP0198 A SYSTEMATIC REVIEW TO INFORM THE EULAR POINTS TO CONSIDER WHEN ANALYSING AND REPORTING COMPARATIVE EFFECTIVENESS RESEARCH WITH OBSERVATIONAL DATA IN RHEUMATOLOGY2020 Annals of the Rheumatic Diseases conference-abstract Mathematics Advanced Causal Inference Techniques Open access
Kim Lauper, Joanna Kedra, Martinus de Wit, Bruno Fautrel, Thomas Frisell, Kimme Leanne Hyrich, +12 more
1citations -
ABS0718 AGE AS THE MAIN PREDICTOR FOR RHEUMATOID ARTHRITIS INITIAL TREATMENT: A MACHINE LEARNING ANALYSIS USING DATA FROM METEOR REGISTRY2025 Annals of the Rheumatic Diseases conference-abstract Medicine Rheumatoid Arthritis Research and Therapies Open access
David Vega‐Morales, Sytske Anne Bergstra, A Chopra, Wendy Marisol Orzúa-de la Fuente, Elsa Vieira‐Sousa, Nimmisha Govind
0citations -
POS0120 REDUCING SELECTION BIAS WHILE MAINTAINING PRECISION THROUGH AN INTEGRATED ANALYSIS: 2-YEAR LONGITUDINAL ANALYSIS OF IMAGING OUTCOMES IN THE SPONDYLOARTHRITIS CAUGHT EARLY COHORT2025 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments Open access
Floris A van Gaalen, Manouk de Hooge, M. van Lunteren, Mary Lucy Marques, M. Reijnierse, Roberta Ramonda, +5 more
0citations -
P56 Prolonged benefit of filgotinib in patients with ulcerative colitis in SELECTION2023 Poster presentations conference-abstract Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease
Ian Beales, David Laharie, Andreas Sturm, Taku Kobayashi, Takayuki Matsumoto, Alessandra Faria Oortwijn, +4 more
0citations -
DOP37 Efficacy and safety of filgotinib in patients with Ulcerative Colitis stratified by age: Post hoc analysis of the phase 2b/3 SELECTION and SELECTIONLTE studies2022 Journal of Crohn s and Colitis conference-abstract Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access
Stefan Schreiber, Edward V. Loftus, Christian Maaser, Silvio Danese, C Rudolph, Rob Jongen, +2 more
5citations -
P393 Effect of filgotinib on anaemia in patients with Ulcerative Colitis in SELECTION2023 Journal of Crohn s and Colitis conference-abstract Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access
Roberta Loveikyte, Alessandra Faria Oortwijn, B Eskens, C Jamoul, K. Muller, A van der Meulen-de Jong
3citations -
P551 Benefit–risk trade-offs and patient preferences for therapy selection in Ulcerative Colitis: a multi-country preference study2024 Journal of Crohn s and Colitis conference-abstract Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access
Javier P. Gisbert, Stefan Schreiber, Corey Allan Siegel, Fernando Magro, Anna Jus, Chiara L. Whichello, +4 more
1citations -
P678 Long-term efficacy, safety and health-related quality of life in patients who achieved comprehensive disease control with filgotinib in SELECTION: analysis of ~3 years in SELECTIONLTE2024 Journal of Crohn s and Colitis conference-abstract Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access
B G Feagan Senior Scientific Officer, Katsuyoshi Matsuoka, Gerhard Rogler, David Laharie, Severine A.R.A. Vermeire, Silvio Danese, +8 more
0citations -
P517 Re-treatment with filgotinib in patients with Ulcerative Colitis following treatment interruption: Analysis of the SELECTION and SELECTIONLTE studies2022 Journal of Crohn s and Colitis conference-abstract Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease
Severine A.R.A. Vermeire, Brian G. Feagan, Laurent Peyrin‐Biroulet, Alessandra Faria Oortwijn, Margaux Faes, Gerhard Rogler
2citations -
P690 Prolonged benefit of filgotinib in patients with Ulcerative Colitis in SELECTION2023 Journal of Crohn s and Colitis conference-abstract Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access
David Laharie, A Sturm, Taku Kobayashi, Takayuki Matsumoto, Alessandra Faria Oortwijn, C Jamoul, +2 more
1citations